FOCUS ON ALS

Genova, september 27th -28th -29th 2018

 

 

FOCUS ON ALS 2018 is an important scientific event organized jointly between the Italian association for ALS (AISLA), the Italian Foundation for the research on ALS (AriSLA) and the second edition of MND “Motor Neuron Diseases – Molecular and cellular basis of vulnerability” meeting, to provide an update of the recent discoveries in the field of the motor neuron disease and new promising hypotheses for its cure. It is a highly informative event, both for researchers and for doctors and patients, focusing on the purely scientific aspect in the first two days and ending with a large space dedicated to the explanation of the issues previously addressed to an audience of non-professionals, with the intent of bringing patients and family members as close as possible to the research world.

The scientific meeting will present and discuss several aspects of the complexity of motor neuron diseases based on the following main topics:

  • Mechanisms of motor neuron vulnerability with respect to genetic hereditary mutation
  • Motor Neuron interaction with surrounding and target cells, glia and muscles
  • The new frontiers of therapeutic strategies, cellular, molecular and genetic

Each section will host 2-3 internationally distinguished scientists in the field. Ample space will also be dedicated to free presentations and communications through posters that represent the fervent progress in the ALS research from various groups that deal with it.

The final day a Plenary Lecture will aim to bring patients and family members closer to research by explaining the challenges and choices faced by researcher in order to offer therapeutic solutions to patients to fight the illness through the emerging strategies and underlining the importance of the patients’ contribution. This will be followed by two parallel workshops:

one scientific will be dedicated to the advanced tools in ALS research which will include un update on new animal and cellular models, including iPSC-derived models and high-throughput screening technologies for targets and potential therapies. This workshop intends to provide an update of the recent discoveries and to generate a fruitful discussion between the speakers and the participants.

In the other clinical 3 major themes will be developed: the first concerning clinical trials, the second will be dedicated to two AISLA projects: «ALS National Registry» and «ALS National Biobank» and a final session will focus on the «state of the art of Edaravone», a drug recently introduced in Italy for ALS patients.